SCHEMBL21274552

SCHEMBL21274552

CNc1nc(-c2cccc(-c3cccc(-c4cnc(CN5CC6(CCC(=O)N6)C5)c(OC)n4)c3Cl)c2Cl)cnc1CN1CC2(CCC(=O)N2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PDCD1 Q15116 20/20 1.00
▸ CD274 Q9NZQ7 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30529834 1.00 PDCD1 (1.00) PDCD1CD274
SCHEMBL21290638 0.93 PDCD1 (1.00) PDCD1CD274
SCHEMBL21290637 0.93 PDCD1 (1.00) PDCD1CD274
SCHEMBL26317991 0.90 PDCD1 (0.82) PDCD1CD274
SCHEMBL21290581 0.89 PDCD1 (1.00) PDCD1CD274
SCHEMBL21290996 0.89 PDCD1 (1.00) PDCD1CD274
SCHEMBL21290022 0.89 PDCD1 (1.00) PDCD1CD274
SCHEMBL25610028 0.89 PDCD1 (0.90) PDCD1CD274
SCHEMBL21290900 0.89 PDCD1 (1.00) PDCD1CD274
SCHEMBL21290925 0.88 CD274 (1.00) PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270195-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2025-08-28 — — US disclosed
EP-4227302-A1 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2023-08-16 — — EP disclosed
EP-4227302-A1 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2023-08-16 — — EP disclosed
US-20230212155-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2023-07-06 — — US disclosed
EP-3752501-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2023-04-19 — — EP disclosed
US-11555029-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2023-01-17 — — US disclosed
US-20210053946-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-02-25 — — US disclosed
US-20210053946-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-02-25 — — US disclosed
EP-3752501-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2020-12-23 — — EP disclosed
US-10710986-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-14 — — US disclosed
US-10710986-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-14 — — US disclosed
US-20190270727-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2019-09-05 — — US disclosed
US-20190270727-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2019-09-05 — — US disclosed
WO-2019160882-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2019-08-22 — — WO disclosed
WO-2019160882-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2019-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11555029-B2 PD-1/PD-L1 inhibitors PDCD1, CD274, PDCD1LG2 PDCD1 1/4885CD274 2/4885
US-20230212155-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 PDCD1 1/4885CD274 2/4885
US-20210053946-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 PDCD1 1/4885CD274 2/4885
US-20250270195-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 PDCD1 1/4885CD274 2/4885
US-10710986-B2 PD-1/PD-L1 inhibitors PDCD1, CD274, PDCD1LG2 PDCD1 1/4885CD274 2/4885
US-20190270727-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 PDCD1 1/4885CD274 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback